Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. We have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a protective “do not eat” signal that blocks the ability of certain immune cells to destroy the tumor. By blocking this “do not eat” signal with decoy receptors, we aim to unmask tumor cells and make them visible to, and eradicated by, the immune system.
View Top Employees from Trillium Therapeutics Inc.| Website | http://www.trilliumtherapeutics.com |
| Ticker | TRIL |
| Revenue | $11 million |
| Employees | 29 (29 on RocketReach) |
| Founded | 2004 |
| Address | 100 Cambridgepark Dr, Ste 510, Cambridge, Massachusetts 02140, US |
| Phone | (416) 595-0627 |
| Technologies |
JavaScript,
HTML,
PHP
+80 more
(view full list)
|
| Category | Organizations, Education, Business Services, Biotechnology Research, Biopharma, Biotechnology, Health Care, Science and Engineering, Clinical Trials, Therapeutics |
| Web Rank | 4 Million |
| Keywords | trillium therapeutics, trillium biotech, trillium therapeutics inc., trillium pharma |
| Competitors | ALX Oncology, ESSA Pharma, EpicentRx, Inc., Homology Medicines, Inc., Leap Therapeutics |
| SIC | 873, 87 |
| NAICS | 5417, 54, 541712, 541, 54171 |
Looking for a particular Trillium Therapeutics Inc. employee's phone or email?
Trillium Therapeutics Inc. Questions
The Trillium Therapeutics Inc. annual revenue was $11 million in 2023.
Penka Petrova is the Chief Development Officer of Trillium Therapeutics Inc..
29 people are employed at Trillium Therapeutics Inc..
Trillium Therapeutics Inc. is based in Cambridge, Massachusetts.
The NAICS codes for Trillium Therapeutics Inc. are [5417, 54, 541712, 541, 54171].
The SIC codes for Trillium Therapeutics Inc. are [873, 87].
Top Trillium Therapeutics Inc. Employees
-
1
-
14
-
2
Related Companies
